Nasdaq Nbix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq nbix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Nbix Today - Breaking & Trending Today

Allegheny Financial Group LTD Buys New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Allegheny Financial Group LTD purchased a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,698 shares of the company’s stock, valued at approximately $224,000. Several other hedge funds and other institutional investors have also […] ....

United States , Neurocrine Biosciences , Ingrid Delaet , Jpmorgan Chase Co , Great Lakes Advisors , Exchange Commission , Neurocrine Biosciences Company Profile , Level Four Advisory Services , Needham Company , Allegheny Financial Group , Panagora Asset Management Inc , Neurocrine Biosciences Inc , Fiera Capital Corp , Quadrant Capital Group , Securities Exchange Commission , Goldman Sachs Group , Free Report , Four Advisory Services , Lakes Advisors , Asset Management , Capital Corp , Capital Group , Director Richard , Visit Holdingschannel , Neurocrine Biosciences Daily , Nasdaq Nbix ,

Canaccord Genuity Group Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $164.00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price upped by Canaccord Genuity Group from $154.00 to $164.00 in a research note issued to investors on Thursday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock. NBIX has been the subject of a number of other reports. Barclays upped their […] ....

United States , Neurocrine Biosciences , Redhawk Wealth Advisors Inc , Cantor Fitzgerald , Goldman Sachs Group , Needham Company , Canaccord Genuity Group , Neurocrine Biosciences Inc , Roman Butler Fullerton Co , Securities Exchange Commission , Free Report , Genuity Group , Moderate Buy , Get Free Report , Director Richard , Exchange Commission , Wealth Advisors , Minvest Partners , Roman Butler Fullerton , Neurocrine Biosciences Daily , Nasdaq Nbix , Boost Price Target , Canaccord Genuity Group Inc ,

Citigroup Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $150.00

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Citigroup from $140.00 to $150.00 in a research report released on Friday, Benzinga reports. The firm currently has a neutral rating on the stock. Other analysts also recently issued research reports about the company. Oppenheimer raised their price objective on Neurocrine Biosciences from […] ....

Los Angeles , United States , Neurocrine Biosciences , Davidw Boyer , Ingrid Delaet , Needham Company , Cantor Fitzgerald , Vanguard Group Inc , Neurocrine Biosciences Inc , Capital Partners , Jpmorgan Chase Co , Los Angeles Capital Management , Neurocrine Biosciences Company Profile , Brown Advisory Inc , Securities Exchange Commission , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Angeles Capital Management , Neurocrine Biosciences Daily , Nasdaq Nbix , Boost Price Target , Citigroup Inc ,

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Increased to $216.00 by Analysts at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price increased by Oppenheimer from $200.00 to $216.00 in a research report report published on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock. Several other equities analysts have also weighed in on the company. Wells Fargo & Company upgraded Neurocrine […] ....

United States , Davidw Boyer , Eric Benevich , Neurocrine Biosciences , Goldman Sachs Group , Central Pacific Bank Trust Division , Fidelis Capital Partners , Wells Fargo Company , Mediolanum International Funds Ltd , Daiwa Securities Group Inc , Neurocrine Biosciences Company Profile , Securities Exchange Commission , Neurocrine Biosciences Inc , Free Report , Moderate Buy , Get Free Report , Exchange Commission , International Funds Ltd , Management Fondsmaeglerselskab , Pacific Bank Trust Division , Securities Group , Neurocrine Biosciences Daily , Nasdaq Nbix , Boost Price Target , Oppenheimer Holdings Inc ,

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $216.00 at Oppenheimer

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by Oppenheimer from $200.00 to $216.00 in a research note issued to investors on Thursday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the stock. Other equities research analysts have also issued reports about the company. Citigroup reduced their price objective on […] ....

United States , Neurocrine Biosciences , Eric Benevich , Lindbrook Capital , Neurocrine Biosciences Inc , Benjaminf Edwards Company Inc , Mather Group , Goldman Sachs Group , Needham Company , Wells Fargo Company , Edgerock Capital , Free Report , Moderate Buy , Get Free Report , Director Richard , Rock Capital , Neurocrine Biosciences Daily , Nasdaq Nbix , Boost Price Target , Oppenheimer Holdings Inc ,